{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:34:15Z","timestamp":1787070855948,"version":"build-2736575974"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>The aim of this study is implementation and establishment of standard operating procedure for permanent prostate implant brachytherapy technique using BARC I-125 Ocu-Prosta seeds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      The transrectal ultrasound (US)-guided procedure was used for permanent implant procedure. The Best\n                      <jats:sup>\u00ae<\/jats:sup>\n                      Sonalis\u2122 US Imaging System and Best NOMOS\u2122 Treatment Planning system was used for volume study and implant procedure. The BARC provided I-125 Ocu-Pro radioactive seeds were implanted into the patient with help of Mick\n                      <jats:sup>@<\/jats:sup>\n                      Applicator. The implant was performed based on pre-implant dosimetry and intraoperative planning performed during implant procedure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The necessary quality assurance tests were performed for US system before clinical use. The boost dose of 110 Gy was prescribed to the prostate volume of 34.71 cc. About 48 seeds with activity of 0.35 mCi (each) implanted into the prostate volume with reference to intraoperative planning. At the end of procedure, the patient underwent abdomen fluoroscopic examination, to ensure the seed counts in the prostate volume. The day after the implant, the patient was discharged. One month later a planning computed tomography and treatment planning was performed for seed position and dose verification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Low dose rate permanent implant brachytherapy has the advantage of being a one-time procedure and the existing long term follow-up supports its excellent outcome and low morbidity. BARC-BRIT is supplying the loose\n                      <jats:sup>125<\/jats:sup>\n                      I seeds. These seeds can be easily implanted into the patient using Mick applicator. However, the pre-implant seed preparation and implant procedure may result some radiation exposure to staff involved. The radiation dose can be minimized with good practice. This report is one patient pilot study and intended to test the implant systems and standard operative procedure henceforth for permanent implant brachytherapy procedure.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_424_20","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T03:13:21Z","timestamp":1623986001000},"page":"340-347","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Prostate permanent implant brachytherapy with BARC I-125 Ocu-Prosta seeds"],"prefix":"10.4103","volume":"17","author":[{"given":"Siddanna R.","family":"Palled","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathiyan","family":"Saminathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanvir","family":"Pasha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Naveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. M.","family":"Ganesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Lokesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20241021","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4103\/0970-1591.174774","article-title":"Demography and disease characteristics of prostate cancer in India","volume":"32","author":"Hariharan","year":"2016","journal-title":"Indian J Urol"},{"key":"R2-6-20241021","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.mgene.2014.07.007","article-title":"Epidemiology of prostate cancer in India","volume":"2","author":"Jain","year":"2014","journal-title":"Meta Gene"},{"key":"R3-6-20241021","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.1996.14.1.304","article-title":"Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: The jury is still out","volume":"14","author":"D'Amico","year":"1996","journal-title":"J Clin Oncol"},{"key":"R4-6-20241021","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0022-5347(17)60906-6","article-title":"Retropubic implantation to iodine 125 in the treatment of prostatic cancer","volume":"108","author":"Whitmore","year":"1972","journal-title":"J Urol"},{"key":"R5-6-20241021","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1118\/1.3006337","article-title":"AAPM task group 128: Quality assurance tests for prostate brachytherapy ultrasound systems","volume":"35","author":"Pfeiffer","year":"2008","journal-title":"Med Phys"},{"key":"R6-6-20241021","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.radonc.2019.02.008","article-title":"GEC-ESTRO ACROP recommendations on calibration and traceability of LE-LDR photon-emitting brachytherapy sources at the hospital level","volume":"135","author":"Perez-Calatayud","year":"2019","journal-title":"Radiother Oncol"},{"key":"R7-6-20241021","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5114\/jcb.2012.29370","article-title":"Prostate cancer brachytherapy: Guidelines overview","volume":"4","author":"Wojcieszek","year":"2012","journal-title":"J Contemp Brachytherapy"},{"key":"R9-6-20241021","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.brachy.2011.07.005","article-title":"American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy","volume":"11","author":"Davis","year":"2012","journal-title":"Brachytherapy"},{"key":"R11-6-20241021","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1118\/1.3246613","article-title":"AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137","volume":"36","author":"Nath","year":"2009","journal-title":"Med Phys"},{"key":"R14-6-20241021","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0969-8043(02)00099-4","article-title":"A novel approach for the adsorption of 125I on silver wire as matrix for brachytherapy for the treatment of eye and prostate cancer","volume":"57","author":"Mathew","year":"2002","journal-title":"Appl Rad Isot"},{"key":"R15-6-20241021","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0969-8043(03)00152-0","article-title":"Comparison of methods for preparation of 125I brachytherapy source cores for the treatment of eye cancer","volume":"59","author":"Manolkar","year":"2003","journal-title":"Appl Radiat Isot"},{"key":"R16-6-20241021","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF03178859","article-title":"Dosimetry parameters of BARC OcuProsta I-125 seed source","volume":"28","author":"Sharma","year":"2005","journal-title":"Australas Phys Eng Sci Med"},{"key":"R17-6-20241021","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1118\/1.2959723","article-title":"Third-party brachytherapy source calibrations and physicist responsibilities: Report of the AAPM Low Energy Brachytherapy Source Calibration Working Group","volume":"35","author":"Butler","year":"2008","journal-title":"Med Phys"},{"key":"R18-6-20241021","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1118\/1.598721","article-title":"Permanent prostate seed implant brachytherapy: Report of the American Association of Physicists in Medicine Task Group No.64","volume":"26","author":"Yan","year":"1999","journal-title":"Med Phys"},{"key":"R19-6-20241021","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1120\/jacmp.v17i3.6105","article-title":"Addendum to brachytherapy dose-volume histogram commissioning with multiple planning systems","volume":"17","author":"Gossman","year":"2016","journal-title":"J Appl Clin Med Phys"},{"key":"R20-6-20241021","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1118\/1.3481514","article-title":"Assessment of normal tissue complications following prostate cancer irradiation: Comparison of radiation treatment modalities using NTCP models","volume":"37","author":"Takam","year":"2010","journal-title":"Med Phys"},{"key":"R21-6-20241021","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0360-3016(99)00351-X","article-title":"The American brachytherapy society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis","volume":"46","author":"Nag","year":"2000","journal-title":"Int J Radiat Biol Oncol Phys"},{"key":"R22-6-20241021","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/BF03178396","article-title":"The role of post-implant dosimetry in the quality assessment of prostate implants. The RAH experience","volume":"29","author":"Marcu","year":"2006","journal-title":"Australas Phys Eng Sci Med"},{"key":"R23-6-20241021","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1118\/1.4725173","article-title":"Quality indicators and technique for analyzing permanent I-125 prostate seed implants: Seven years post implant dosimetry evaluation","volume":"39","author":"Marcu","year":"2012","journal-title":"Med Phys"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_424_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:45Z","timestamp":1787067465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_424_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_424_20","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}